CERO

Announcements

Nothing here yet

Daily updates

Nothing here yet

FDA designations

• CERo Therapeutics Receives FDA Fast Track Designation for CER-1236 in Acute Myeloid Leukemia (AML)Sep 5, 2025
• "FDA Grants Orphan Drug Designation to CER-1236 for the Treatment of Acute Myeloid Leukemia (AML)"Jun 17, 2025

News

• CERo Therapeutics announces third dose for patient in Phase 1 clinical trial of CER-1236 in acute myeloid leukemiaOct 21, 2025
• CERo Therapeutics announces completion of first cohort of Phase 1 clinical trial of CER-1236 in acute myeloid leukemiaOct 13, 2025
• CERo Therapeutics progresses Phase 1 CER-1236 AML trial with dosing of third patient in initial dose cohortSep 23, 2025
• CERo Therapeutics announces dose intensification in Phase 1 study of CER-1236 in acute myeloid leukemiaSep 8, 2025
• CERo Therapeutics receives FDA Fast Track designation for CER-1236 in acute myeloid leukemiaSep 5, 2025